Resverlogix completes patient recruitment in Phase 2 ASSERT clinical study

Resverlogix (TSX:RVX) has completed patient enrolment in the Phase 2 ASSERT clinical study of its lead cholesterol drug RVX-208, five months ahead of schedule. “At this rate we could be seeing the final dosed patient in May, 2010,” CEO Donald McCaffrey said in a statement. “In the second half of 2010, we look forward to [...]

Resverlogix in $25 million standby financing

Resverlogix has signed a standby equity distribution agreement with YA Global Master SPV, a fund managed by Yorkville Advisors, which gives Resverlogix an option to sell up to $25-million of common shares to YA. “This agreement will provide Resverlogix with the flexibility to draw strategic amounts of capital at its discretion,” Resverlogix CEO Donald McCaffrey [...]